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Summary
Background.  —  Percutaneous  pulmonary  valve  replacement  (PPVR)  has  achieved  standard  of
care for  the  management  of  dysfunctional  right  ventricular  outﬂow  tract.
Aim.  —  Because  of  increasing  reports  of  Melody® valve  (Medtronic,  Inc.,  Minneapolis,  MN,  USA)
infective  endocarditis  (IE),  we  aimed  to  evaluate  its  incidence  and  predictors  of  occurrence.
Methods.  —  We  collected  data  on  all  patients  who  received  a  Melody  valve  in  the  pulmonary
position  from  2009  to  2012.
Results.  —  A  total  of  86  consecutive  patients  underwent  PPVR  from  2009  to  2012;  of  these,
ﬁve developed  IE  (5.8%).  Freedom  from  IE  was  91%  at  50  months.  Baseline  demographics,  type
of conduit,  PPVR  procedural  success,  residual  gradients  and  in  situ  duration  of  Melody  valve
were similar  in  IE  and  non-IE  patients.  A  signiﬁcant  number  of  IE  patients  had  additional  unpro-
tected invasive  procedures  during  follow-up  and  abruptly  discontinued  antiplatelet  therapy
(P =  0.0139  and  P  =  0.002,  respectively).  The  cumulative  probability  of  survival  without  cardio-
vascular events  for  IE  patients  was  20%  at  20  months,  compared  with  98.1%  for  non-IE  patients
(P <  0.0001).  Death  was  statistically  associated  with  IE.
Abbreviations: AAT, Antiaggregant therapy; CHD, Congenital heart disease; IE, Infective endocarditis; PA, Pulmonary artery; PET, Positron
emission tomography; PPVR, Percutaneous pulmonary valve replacement; RV, Right ventricle; RVOT, Right ventricular outﬂow tract; RVOTO,
RVOT obstruction.
∗ Corresponding author. Hôpital Necker Enfants Malades, Cardiologie Pédiatrique, 149, rue de Sèvres, 75015 Paris cedex, France.
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Conclusion.  —  Early-  and  late-onset  IE  of  the  Melody  valve  is  emerging  as  a  catastrophic  compli-
cation of  PPVR.  Abrupt  aspirin  discontinuation  and  additional  unprotected  invasive  procedures
during follow-up  are  signiﬁcant  predictors  of  Melody  valve  IE.  Owing  to  its  rapidly  progressive
nature, aggressive  invasive  management  should  not  be  delayed.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — Le  remplacement  valvulaire  percutané  (RVP)  est  désormais  considéré  comme  un
traitement  de  première  ligne  des  dysfonctions  de  la  voie  d’éjection  droite.
Objectif. —  À  cause  de  rapports  croissants  d’endocardites  sur  Melody® (Medtronic,  Inc.,  Min-
neapolis, MN,  États-Unis),  nous  avons  évalué  son  incidence  et  les  facteurs  de  risque  de  survenue.
Méthodes.  —  Nous  avons  collecté  les  données  de  tous  les  patients  ayant  eu  la  mise  en  place
d’une valve  Melody  en  position  pulmonaire  de  2009  à  2012.
Résultats.  —  Quatre-vingt-six  patients  consécutifs  ont  rec¸u  une  valve  Melody.  Cinq  ont  eu  une
endocardite,  soit  une  incidence  de  5,8  %.  La  survie  actuarielle  sans  endocardite  était  de  91  %  à
50 mois.  Les  données  démographiques,  le  type  de  conduits,  le  gradient  résiduel,  la  durée  de  la
valve étaient  similaires  dans  les  groupes  avec  et  sans  endocardites.  Un  nombre  signiﬁcatif  de
patients avec  endocardites  ont  eu  des  actes  invasifs  non  protégés  au  cours  du  suivi  et  ont  inter-
rompu leur  traitement  anti-plaquettaire  subitement  (respectivement  p  =  0,0139  et  p  =  0,002).
Les probabilités  cumulées  de  survie  sans  événement  cardiovasculaire  étaient  de  20  %  et  98,1  %
à 20  mois,  respectivement  dans  les  groupes  avec  endocardites  et  sans  endocardite  (p  <  0,0001).
Le décès  était  statistiquement  associé  à  l’endocardite.
Conclusion.  — La  survenue  d’endocardites  de  la  valve  Melody  émerge  comme  une  complication
catastrophique  du  remplacement  valvulaire  percutané.  L’interruption  brutale  de  l’aspirine  et
les actes  invasifs  non  protégés  au  cours  du  suivi  sont  prédictifs  d’endocardites  sur  Melody.  En
raison de  leur  caractère  sub-aigu,  il  est  nécessaire  de  les  traiter  de  manière  agressive  et  rapide.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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aackground
ercutaneous  pulmonary  valve  replacement  (PPVR)  is  now
ecognized  as  a  treatment  for  dysfunctional  right  ventricular
utﬂow  tract  (RVOT)  [1].  The  device  was  initially  devel-
ped  with  the  aim  of  extending  the  lifespan  of  conduits
urgically  placed  between  the  right  ventricle  (RV)  and  the
ulmonary  arteries  (PAs)  in  patients  with  various  congenital
eart  diseases  (CHDs)  [2].  After  more  than  a  decade,  its  util-
ty  has  evolved  to  include  patients  with  dysfunctional  native
utﬂow  tracts  [3].  The  Melody® valve  (Medtronic,  Inc.,  Min-
eapolis,  MN,  USA)  is  used  most  frequently  for  PPVR,  and
s  made  of  a  bovine  jugular  vein  valve  mounted  on  a  plat-
num  stent.  PPVR  using  the  Edwards  SAPIEN  valve  (Edwards
ife  Sciences,  Irvine,  CA,  USA)  has  been  reported;  however,
ong-term  follow-up  outcomes  are  awaited  [4].  PPVR  can  be
afely  performed  with  very  low  morbidity  and  mortality  and
xcellent  long-term  haemodynamic  results  in  the  majority
f  patients  [5—8];  it  offers  a  good  alternative  to  surgery  for
atients  with  haemodynamically  signiﬁcant  RVOT  diseases.
espite  such  promising  results,  there  are  increasing  num-
ers  of  reports  of  Melody  valve  infective  endocarditis  (IE)
5,8,9].  So  far,  however,  there  is  little  information  on  the
ncidence,  predictors  and  potential  risk  markers  associated
ith  IE  in  patients  with  Melody  valves  [5—8].
This  study  was  undertaken  to  evaluate  the  incidence  of  IE
n  a  cohort  of  patients  who  had  undergone  Melody  PPVR,  and
T
c
p
co  identify  potential  risk  markers  in  patients  who  developed
E  in  this  prospective  survey.
ethods
he  primary  endpoint  was  to  evaluate  the  incidence  and  pre-
ictors  of  IE,  and  to  extensively  study  the  proﬁle  of  patients
ith  IE.  IE  was  diagnosed  based  on  modiﬁed  Duke  criteria
ith  occurrence  of  bacteraemia  with  at  least  two  posi-
ive  blood  cultures  and  vegetations  seen  on  transthoracic
r  transoesophageal  echocardiography  or  positive  positron
mission  tomography  (PET)  scan.
The  secondary  endpoint  was  to  identify  associated
isk  markers,  which  were  divided  into  three  groups:
reprocedural  characteristics,  perprocedural  factors  and
ostprocedural  data.
atient selection
ll  consecutive  patients  who  underwent  Melody  PPVR  for
ysfunctional  RVOT  between  April  2009  and  June  2012  at
 single  institution  were  included  in  this  prospective  study.
he  study  was  conducted  in  accordance  with  local  ethics
ommittee  guidelines;  informed  consent  was  obtained  from
atients  and/or  their  parents  after  explanation  of  the  pro-
edure.
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Procedural  complications  occurred  in  ﬁve  patients  (none  inPredictors  of  Melody® valve  endocarditis  
At  the  time  of  the  procedure,  no  patient  had  ongoing
infection.  During  the  procedure,  prophylactic  antibiotics
(cefamandol)  were  administered  and  continued  for  24  hours
(three  doses  in  total).  In  case  of  allergy,  vancomycin  was
given  once  during  the  procedure.  Heparin  was  given  during
the  procedure,  followed  by  low-molecular-weight  heparin
for  the  next  24  hours  (three  doses  in  total).  Patients  were
prescribed  lifelong  full-dose  aspirin  (100  mg/day)  after  PPVR
or  clopidogrel  in  case  of  allergy.
Preprocedural,  perprocedural  and  postprocedural  data
were  collected  prospectively.  Demographic  characteristics,
numbers  of  surgeries  and  cardiac  catheterizations,  type
of  conduit,  history  of  severe  infection  and  endocardi-
tis,  co-morbidities  (deﬁned  as  signiﬁcant  chronic  medical
conditions,  including  genetic  abnormalities,  undeﬁned  syn-
dromes,  chronic  infection)  and  echocardiography  were
recorded  for  all  patients.  Procedural  data  (length  of  the  pro-
cedure,  access,  haemodynamic  data,  associated  procedures
and  complications)  were  recorded.
After  PPVR,  all  patients  were  followed  up  at  1,  3,  6  and
12  months  and  yearly.  The  last  gradient  across  the  Melody
valve  on  echocardiogram  was  reviewed.  The  evolution  of
the  gradient  over  time  was  evaluated  by  subtraction  of  the
haemodynamic  gradient  measured  in  the  catheterization
laboratory  after  Melody  PPVR  from  the  gradient  measured
on  the  last  echocardiogram.  The  gradient  over  the  RVOT  at
the  time  of  IE  was  also  compared  with  the  gradient  at  the  last
echocardiogram  before  IE.  Blood  work  and  imaging  modali-
ties  to  diagnose  IE,  the  evolution  of  the  disease,  the  time  to
diagnosis  and  management,  including  surgery,  were  noted.
Statistical analysis
SAS  software  version  9.3  (SAS  Institute,  Inc.,  Cary,  NC,
USA)  was  used  for  statistical  analysis.  Nominal  variables  are
expressed  as  numbers  and  percentages  and  were  compared
using  Fisher’s  exact  test  or  the  chi2 test,  as  appropriate.
Ordinal  variables  are  presented  as  means  ±  standard  devia-
tions  and  were  compared  using  Wilcoxon’s  rank  sum  test.
Continuous  variables  are  expressed  as  means  ±  standard
deviations  and  were  compared  using  the  independent  varia-
bles  t-test.  All  tests  were  two-sided  and  a  P  value  <  0.05
was  considered  statistically  signiﬁcant.  Survival  curves  were
constructed  using  the  Kaplan—Meier  method.  Groups  were
compared  using  log-rank  statistics.  The  risk  factors  for
IE  were  studied  using  univariate  Cox  proportional  hazards
survival  analyses.  The  risk  markers  of  IE  were  studied  by  uni-
variate  and  multivariable  Cox  proportional  hazards  survival
analyses.  The  variables  used  in  the  multivariable  analysis
were  those  with  a  P  value  <  0.05  in  the  univariate  analy-
sis.
Results
From  2009  to  2012  (a  4-year  period),  86  consecutive
patients  underwent  Melody  PPVR.  Five  patients  developed
IE  (5.8%,  95%  CI  0.9—10.7%)  during  a  mean  follow-up  period
of  23.6  ±  15  months  (range  2.6—28.3  months  after  Melody
PPVR).  The  detailed  proﬁle  of  patients  with  IE  is  presented
in  Table  1.  Three  patients  had  early  (<  1  year)  and  two
patients  had  late  (>  1  year)  Melody  valve  IE.  At  admission,
t
i
b
w99
ll  patients  had  a  history  of  fever  and  malaise.  Microorgan-
sms  were  identiﬁed  in  all  patients.  Vegetations  were  seen
n  echocardiography  (transthoracic  or  transoesophageal)
n  three  patients,  one  patient  had  a  positive  PET  scan
nd  one  patient  presented  with  cardiogenic  shock  and
evere  obstruction  of  the  RVOT,  but  no  thrombus  or  vege-
ation  was  seen  by  standard  imaging.  Autopsy  examination
howed  well-preserved  stent  struts  with  large  loose  obstruc-
ive  vegetations  made  of  ﬁbrinous  material  ﬁlling  up  the
usps.  Microorganisms  were  found  in  the  histology  and  valve
ulture.
All  patients  with  IE  had  an  increase  in  their  gradient
cross  the  RVOT  when  comparing  gradients  on  the  last
chocardiogram  and  at  hospital  admission,  conﬁrming  the
nvolvement  of  the  Melody  valve.
Patients  1,  2  and  5  presented  with  rapidly  progressive
evere  obstruction  and  heart  failure.  Patients  1  and  2  died
ventricular  ﬁbrillation)  within  12  hours  of  hospital  admis-
ion:  one  at  arrival  in  the  operating  room;  and  one  in
he  cardiac  intensive  care  unit  during  the  night  before  the
urgery.  Patient  5  needed  cardiac  catheterization  to  relieve
bstruction  of  the  RVOT  (bare-metal  stent  insertion)  and
ubsequent  surgery  to  explant  the  Melody  and  treat  concom-
tant  aortic  valve  IE.  Patient  4 with  Staphylococcus  aureus
E  was  stabilized  with  antibiotics,  and  balloon  dilatation  of
VOT  obstruction  (RVOTO)  was  performed  before  discharge.
owever,  this  patient  developed  severe  heart  failure  with-
ut  residual  RVOTO  and  died  6  months  after  the  onset  of
E,  despite  sustained  sterilization  of  the  IE.  Patient  3  was
reated  medically  and  is  currently  free  of  infection.
reprocedural data
atients  with  IE  tended  to  be  older  than  those  with-
ut  IE  (mean  age  at  implantation  29.8  ±  16.3  years  vs
3.5  ±  10  years  for  patients  without  IE)  (Table  2).  Most  of
he  patients  with  IE  were  men  (4  of  5).  Co-morbidities  were
oted  in  18  patients  (20%)  and  were  associated  with  a  trend
owards  developing  IE  (P  =  0.06).  The  numbers  of  previous
urgeries,  cardiac  catheterizations  and  stent  implantations
n  the  RVOT,  the  type  of  conduit,  the  maximal  gradient
cross  RVOT  and  the  interval  between  surgery  and  PPVR
ere  similar  in  both  groups.  In  this  cohort,  ﬁve  patients
ad  a  history  of  IE  and  six  had  a  history  of  severe  infections
all  >  1  year  before  PPVR);  these  were  not  found  to  be  a  risk
arker  for  IE  (P  =  0.34  and  1,  respectively).  The  presence  of
 stent  in  the  RVOT  was  not  associated  with  occurrence  of
E.
rocedural data
emoral  access  was  achieved  in  84  patients  (97.7%)
Table  3).  The  mean  duration  of  the  procedure  was
9.6  ±  46.5  minutes  and  was  identical  in  the  IE  and  non-
E  groups.  Haemodynamics  were  not  different  in  the  two
roups,  and  the  rate  of  associated  procedure  was  similar.he  IE  group).  In  addition,  the  number  of  stents  used  dur-
ng  the  procedure  and  the  anatomical  data  did  not  differ
etween  groups,  and  haemodynamic  data  following  PPVR
ere  similar.
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Table  1  Proﬁle  and  characteristics  of  patients  with  infective  endocarditis.
Patient  1  Patient  2  Patient  3  Patient  4  Patient  5
Age  at  presentation
(years)
18  26  46  50  14
Sex  Female  Male  Male  Male  Male
Underlying  diagnosis  TOF-PA  TOF-PA  Rheumatic  aortic
stenosis;  Ross
procedure
TOF  Congenital  aortic
stenosis;  Ross
procedure
Co-morbidities  None  None  Heterozygote
beta
thalassaemia
Di  George
Syndrome;  HCV
Portal
cavernoma;
oesophageal
varices
Indication  for  PPVR  Obstruction  Mixed  Obstruction  Mixed;  RV  failure  Mixed
RVOT  characteristics
and  size
Hancock  16  Hancock  18  Homograft  Homograft  26  Carpentier-
Edwards
20
Surgery  to  PVR
(years)
14  15  15  11  4
PPVR  IE  (months)  28.3  2.6  4.5  26  11.9
Previous  IE  None  None  None  None  None
Previous  infection  None  Cerebral  abscess  None  None  None
Residual  lesions:
maximal  velocity
4.7  m/s  3.5  m/s  2.2  m/s  2.2  m/s  2.1  m/s
Presentation  Fever;  RVOTO;
RV  failure;
Vmax 5.5  m/s
Fever;  RVOTO;  RV
failure;  Vmax
5.9  m/s
Fever;  Vmax 3  m/s  Fever;  RVOTO;  RV
failure;  Vmax
3.5  m/s
Fever;  RVOTO;
Vmax 3.3  then
4.6  m/s
Abrupt  AAT
discontinuation
Yes  Yes  No  Yesa Nob
Cardiac
catheterization
Yes  No  No  Yes  No
Invasive  procedure
post-PPVR
Yes  No  No  Yes  Yesb
Potential
source/portal  of
entry
Lingual
piercing;
abortion  (3
months  before
IE)
Multiple  tooth
decay
None  Flutter  ablation  3
months  before  IE
Hepatic  biopsyb
Involvement  of
other  valves
None  None  None  None  Aortic  valve
Location  of
vegetations
PA  side  PA  side  PA  and  RV  PET  scan  +  PA  side
Diagnosis  with  TTE  +  +
Diagnosis  with  TOE  +
Other  Post  mortem  PET  scan
Pulmonary  valvular
gradient
Severe  Severe  Moderate  Severe  Severe
Causative
microorganism
from  blood
culture
Streptococcus
sanguis
Staphylococcus
epidermidis
Staphylococcus
epidermidis;
methicillin-
sensitive
Staphylococcus
aureus;
methicillin-
sensitive
Streptococcus
sanguis
Initial  treatment
planned
Surgery;  IV
antibiotics
(amoxicillin/
gentamicin)
Surgery  planned;
IV  antibiotics
(gentamycin,
tazobactam-
piperacillin,
vancomycin)
IV antibiotics
(oxacillin/
gentamycin)
IV antibiotics
(oxacillin/
peﬂoxacin);
balloon  dilatation
of  Melody
IV antibiotics
(amoxicillin/
gentamycin);
bare-metal  stent
implantation
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Table  1  (Continued)
Patient  1  Patient  2  Patient  3  Patient  4  Patient  5
Outcome  Cardiogenic
shock;  death
before  surgery
Cardiogenic
shock;  death
before  surgery
Alive;  no  surgery;
stable  gradient
Severe  RV  failure;
no  surgery;  death
6  months  after  IE
Alive  and  well
after  surgery
AAT: antiaggregant therapy; HCV: hepatitis C virus; IE: infective endocarditis; IV: intravenous; PA: pulmonary artery; PET: positron
emission tomography; PPVR: percutaneous pulmonary valve replacement; PVR: pulmonary valve replacement; TOF-PA: tetralogy of Fallot
with pulmonary atresia; RV: right ventricle; RVOT: right ventricular outﬂow tract; RVOTO: right ventricular outﬂow tract obstruction;
Staph: Staphylococcus; Strep: Streptococcus; TOE: transoesophageal echocardiography; TTE: transthoracic echocardiography; Vmax:
maximal velocity.
a On warfarin; AAT stopped 3 months before IE.
ent d
cb Hepatic biopsy complicated by sepsis 6 months before IE; transi
Postprocedural dataMean  follow-up  and  mean  evolution  of  the  gradient  over
time  were  similar  in  the  two  groups  (Table  4).  All  patients
with  IE  had  an  increase  in  the  gradient  across  the  RVOT  when
p
v
a
Table  2  Demographic  characteristics.
Overall
(n  =  86)
Age  (years)  23.9  ±  10.5  
Men/women  51/35  
Body  surface  (m2)  1.6  ±  0.3  
Type  of  CHD  
TOF  22  (25)  
PAVSD  20  (23)  
Truncus  arteriosus  11  (13)  
Aortic  valve  disease  13  (15)  
PS  2  (2)  
TGA-VSD-PS  2  (2)  
DORV  4  (5)  
Other  12  (14)  
Co-morbidities  18  
22q11  deletion 8  
Noonan  syndrome  1  
Other  syndrome  5  
Trisomy  21  1  
Beta  thalassaemia  1  
HCV  2  
Portal  cavernoma  1  
History  of  infections  6  
History  of  endocarditis  5  
Interval  between  last  surgery  and  PPVR  12.9  ±  7  
Contegra  11  
Number  of  cardiac  catheterizations  2.3  ±  2.3  
Number  of  surgeries  1.9  ±  0.85  
Presence  of  stent  in  the  RVOT  
Yes  32  
No  54  
Data are mean ± standard deviation, number (%) or number. CHD: con
hepatitis C virus; IE: infective endocarditis; NS: not signiﬁcant; PA
percutaneous pulmonary valve replacement; PS: pulmonary stenosis; 
great arteries; TOF: tetralogy of Fallot; VSD: ventricular septal defect.
a Two conditions in one patient.iscontinuation of AAT during sepsis due to thrombocytopoenia.
omparing  gradients  on  the  last  echocardiogram  and  at  hos-
ital  admission,  conﬁrming  the  involvement  of  the  Melody
alve.
Eleven  patients  underwent  eleven  invasive  procedures
fter  PPVR  without  antibioprophylaxis;  three  developed  IE.
IE
(n  =  5)
Non-IE
(n = 81)
P
29.8  ±  16.3  23.5  ±  10  0.4
4/1  47/34  0.94
1.8  ±  0.3  1.6  ±  0.3  0.6
0.8
1  21
1  19
0  11
2  11
0  2
1  1
0  4
0  12
3a 15  0.06
1  7
0  1
0  5
0  1
1  0
1  1
1  0
1  5  0.3
0  5  1
12.7  ±  4.6  13.0  ±  7.2  0.9
0  11  1
1.5  ±  1.7  2.3  ±  2.2  0.5
2.2  ±  0.8  1.9  ±  0.8  0.9
0.35
3  29
2  52
genital heart disease; DORV: double outlet right ventricle; HCV:
VSD: pulmonary atresia with ventricular septal defect; PPVR:
RVOT: right ventricular outﬂow tract; TGA: transposition of the
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Table  3  Procedural  data.
Overall
(n  =  86)
IE
(n  =  5)
Non-IE
(n  =  81)
P
Initial  systolic  RV-PA  gradient  (mmHg)  44.9  ±  24.1  47  ±  35  44.7  ±  23.5  0.9
Initial  systolic  RV-Ao  ratio  0.77  ±  0.24  0.75  ±  0.33  0.77  ±  0.24  0.79
Systolic  RV-PA  gradient  post  Melody  (mmHg) 12.4  ±  7.6 12  ±  12.1  12.4  ±  7.3  0.38
Systolic  RV-Ao  ratio  post  Melody 0.42  ±  0.12 0.42  ±  0.13 0.41  ±  0.12  0.9
Associated  procedures 0.63
Overall  60  3  57
Prestenting  58  2  56
PA  stents  14  0  14
Othera 3  1  2
Complicationsb 5  (5.81)  0  (0)  5  (6)  1
Length  of  procedure  (minutes)  89.6  ±  46.5  77  ±  25  90.6  ±  47  0.6
Access  1
Femoral  84  5  79
Jugular  2  0  2
Data are mean ± standard deviation, number or number (%). Ao: aorta; IE: infective endocarditis; NS: not signiﬁcant; PA: pulmonary
artery; RV: right ventricle.
a Ventricular septal defect closure, right coronary artery angioplasty and atrial septal defect closure.
b Conduit rupture (n = 2), rupture of balloon in the right ventricular outﬂow tract (n = 1); transient atrioventricular block (n = 1); partial
covering of right PA (n = 1).
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chen  comparing  IE  and  non-IE  groups,  the  difference  was
ighly  statistically  signiﬁcant  (odds  ratio  13.69,  95%  conﬁ-
ence  interval  1.98—94.52;  P  =  0.0139).
Of  86  patients,  78  were  on  aspirin  (three  had  a  com-
ination  of  antiaggregant  therapy  [AAT]  and  warfarin),
hree  were  on  clopidogrel  (allergy  to  aspirin),  four  were
n  warfarin  only  and  one  patient  had  stopped  AAT.  AAT
iscontinuation  was  found  to  be  a  risk  factor  for  the
evelopment  of  IE  (P  =  0.002).  The  ability  of  aspirin  to
revent  the  onset  of  IE  was  studied  by  univariate  Cox
e
u
s
t
Table  4 Postprocedural  characteristics.
Overall
(n  =  86)
Evolution  of  RVOTO  (mmHg) 18  ±  12  
Unprotected  medical  invasive  acts  11  
Electrophysiology  4  
Cardiac  cath  4  
Other  procedure  3  
Treatment
AAT  81  
No  AAT  5  
Mean  follow-up  (months)  24.08  ±
Outcome  
Alive,  PPVR  78  
Alive,  surgical  Pulmonary  valve  replacement  4  
Death  4  
RVOTO: right ventricular outﬂow tract obstruction; IE: infective e
pulmonary valve replacement.roportional  hazards  survival  analysis  (relative  risk  20.1,
5%  conﬁdence  interval  3.34—120.8;  P  =  0.001).  In  mul-
ivariable  analysis,  only  AAT  prevents  signiﬁcantly  the
isk  of  IE  (P  =  0.020).  Three  of  the  ﬁve  patients  with  IE
ad  their  valves  explanted  (two  at  autopsy,  one  surgi-
ally).  Three  patients  without  IE  had  elective  surgery  with
xplantation  of  the  Melody  valve:  two  because  of  resid-
al  RVOTO  (2.5  and  2  years  after  PPVR);  and  one  during
urgical  aortic  valve  replacement  (the  decision  was  taken
o  perform  surgical  PVR  at  the  time  of  aortic  surgery,
IE
(n =  5)
Non IE
(n  =  81)
P value
27  ±  17  11.7  ±  11  NS
3  8  0.014
1  3
0  4
2  1
3  78  0.002
2  3
 14.9  22.49  ±  12.46  24.18  ±  15  NS
0.004
1  77
1  3
3  1
ndocarditis; AAT: anti-aggregant therapy; PPVR: percutaneous
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despite  good  function  of  the  Melody  valve  3.5  years  after
PPVR).
Freedom  from  IE  was  91%  at  50  months  (Fig.  1).  The  cumu-
lative  probability  of  survival  without  cardiovascular  events
for  the  IE  patients  was  20%  at  20  months,  compared  with
98.1%  for  the  non-IE  patients  (log-rank  83.18;  P  <  0.0001  for
the  overall  difference  in  event  rates;  Fig.  2).  In  the  whole
series,  four  patients  died  during  follow-up:  three  in  the  IE
group  (two  refractory  shocks  during  IE;  one  biventricular
heart  failure  6  months  after  IE  [no  active  infection  at  the
time  of  death])  and  one  in  the  non-IE  group  (biventricular
heart  failure  refusing  heart  transplantation).  In  this  study,
death  was  statistically  associated  with  IE.  Kaplan—Meier
estimates  of  event-free  survival  in  the  IE  and  non-IE  groups
are  shown  in  Fig.  3  (log-rank  7.43;  P  <  0.05).
DiscussionIn  patients  with  CHD,  studies  on  the  incidence,  source,
treatment  and  outcome  of  IE  are  rare  [10,11]. The  inci-
dence  of  IE  is  higher  in  CHD  patients  than  in  the  general
Figure 2. Freedom from cardiovascular events (death, cardiac
interventions). Blue: no infective endocarditis; Green: infective
endocarditis.
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sigure 3. Kaplan—Meier survival curve: Blue: no infective endo-
arditis; Green: infective endocarditis.
opulation,  but  the  prognosis  is  better  [11].  The  portal  of
ntry  of  microbial  agents  may  be  nosocomial  after  an  inva-
ive  procedure  or  community  acquired.  Prognosis  is  worst  in
rosthetic  valve  endocarditis,  and  the  need  for  surgery  is
ore  frequent  than  in  native-valve  IE  [11,12].  Limited  data
re  available  on  transcatheter  pulmonary  valve  endocardi-
is.
ncidence of Melody valve infective
ndocarditis
n  this  series,  ﬁve  cases  of  IE  were  identiﬁed  in  a  cohort
f  86  patients  with  a  mean  follow-up  of  23.6  months;  the
ncidence  is  thus  around  3%  per  year.  The  true  prevalence
r  incidence  of  IE  in  the  global  population  of  patients  with
PVR  is  unknown;  however,  there  are  some  published  case
eports,  case  series  and,  more  recently,  two  clinical  stud-
es  [5,8,13—15]. In  all  the  large  series  published  on  Melody
PVR,  IE  has  been  described  as  a  complication.  Buber  et  al.
nd  McElhinney  et  al.  recently  reported  the  incidence  of
elody  valve  IE  to  be  as  high  as  2.7%  and  5.2%,  respectively
5,8].
iagnostic tools
E  is  diagnosed  based  on  modiﬁed  Duke  criteria,  although
n  patients  with  prosthetic  valves  or  Melody  valves,  cardiac
nvolvement  can  be  difﬁcult  to  determine  with  a  high
egree  of  certainty  because  of  the  prosthesis  artefact  and
he  unusual  anatomy  of  the  RVOT.  Vegetations  were  seen  on
chocardiography  in  only  three  patients  in  our  series.  Some
ther  diagnostic  tools  may  be  helpful,  such  as  intracardiac
chocardiography,  three-dimensional  echocardiography  or
ET  scan  [16].  These  modalities  may  be  useful  in  case  of
ersistent  doubt  about  cardiac  involvement;  of  course,  this
emains  to  be  demonstrated.  More  importantly,  an  increase
n  the  RVOT  gradient  was  present  in  all  patients  with  IE
hen  comparing  the  echocardiogram  at  admission  with
he  latest  echocardiogram  available.  Duke  criteria  should,
n  our  opinion,  be  modiﬁed  for  PPVR;  a  new  increase  in
VOTO  unexplained  by  a structural  complication,  such  as
tent  fracture,  demonstrates  the  valvular  involvement  and
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hould  be  considered  as  a  major  criterion,  similar  to  the
ew  onset  of  pulmonary  regurgitation.  This  might  explain
he  difference  seen  in  incidence  between  studies.  Based
n  these  features,  most  of  the  blood  stream  infections
eported  by  Buber  et  al.  might  be  reclassiﬁed  as  certain  IE,
esulting  in  a  higher  incidence  of  true  IE  [5].
isk markers
n  this  study  of  potential  risk  markers,  many  failed  to  achieve
tatistical  signiﬁcance.  No  risk  marker  was  identiﬁed  among
reprocedural  data.  Patients  with  IE  tended  to  be  older,
lthough  not  signiﬁcantly.  Surprisingly,  male  sex  (a  classical
isk  factor)  was  not  associated  with  IE.  IE  was  not  asso-
iated  with  any  particular  type  of  surgical  conduit,  with
he  presence  or  number  of  stents  in  the  RVOT  or  with  the
natomy  of  RVOT,  as  previously  reported  [7,8]. The  presence
f  co-morbidities  was  not  statistically  signiﬁcant,  although
he  frequency  of  co-morbidities  was  higher  in  the  IE  group.
revious  infection  or  endocarditis  was  not  found  to  be  asso-
iated  with  an  increased  risk  of  IE.  IE  was  not  related  to  a
ore  complicated  or  prolonged  procedure.  Postprocedural
ata  showed  that  the  only  risk  markers  to  achieve  statis-
ical  signiﬁcance  were  abrupt  discontinuation  of  AAT  and
nprotected  invasive  medical  procedures.  In  this  study,  bac-
eraemia  secondary  to  invasive  procedures  might  have  led
o  seeding  on  the  non-bacterial  thrombotic  endocarditis,
hich  was  facilitated  by  the  discontinuation  of  AAT.  Indeed,
n  the  group  of  patients  with  IE,  three  had  AAT  discontinua-
ion  and  one  brief  interruption  of  AAT.  The  role  of  platelets
n  the  pathogenesis  of  vegetation  and  the  severity  of  endo-
arditis,  with  acute  or  chronic  use  of  antiplatelets  reducing
he  need  for  acute  valve  replacement  and  overall  mortality,
ave  been  described  extensively  in  vitro  and  in  vivo  [17—26].
owever,  to  our  knowledge,  there  are  no  data  showing  that
ntiplatelet  therapy  prevents  endocarditis.
hysiopathology of infective endocarditis
esides  platelets  and  antiplatelet  therapy,  other  hypothe-
es  can  be  considered.  IE  results  from  complex  interactions
etween  valvular  or  endocardial  structures  and  endothelium
lood  components.  Damage  to  cardiac  structures  resulting
rom  balloon  dilatation  and  stent  implantation  might  favour
latelet  and  ﬁbrin  deposition,  with  subsequent  microbial
dherence  to  thrombi,  leading  to  IE.  In  addition,  prior
eports  of  IE  in  bovine  conduits  may  suggest  possible  tropism
f  microorganisms  to  the  bovine  material  used  for  making
he  Melody  valve  [27,28].  A  European  Contegra® (Medtronic,
nc.,  Minneapolis,  MN,  USA)  multicentre  study  reported  an
ncidence  of  5-year  freedom  from  IE  of  92%  in  165  patients
29].  Furthermore,  turbulences  in  the  RVOT  may  increase  or
acilitate  the  formation  of  microthombi  in  the  RVOT,  sec-
ndary  to  shear  stress  lesions  of  the  endothelium.  Analysing
oth  anatomical  and  haemodynamic  data,  we  were  unable
o  ﬁnd  statistical  differences  between  patients.
anagementelody  valve  IE  is  similar  to  any  prosthetic  valve  IE,
ith  similar  causative  microbes;  antibiotic  regimens  should,
herefore,  also  be  similar  [12].  Guidelines  for  urgent
t
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ntervention  remain  unchanged.  In  case  of  severe  obstruc-
ion  of  the  RVOT,  emergency  balloon  dilatation  of  the
elody  valve,  with  or  without  bare-metal  stent  insertion,
an  be  performed  to  relieve  the  obstruction  and  stabilize
he  patient.  Transcatheter  intervention  has  been  carried  out
n  two  cases,  with  good  results:  surgery  was  not  required  in
ne  patient;  and  the  other  patient  had  secondary  surgery.
ccording  to  the  European  Society  of  Cardiology  guidelines
30], the  presence  of  congestive  heart  failure  should  prompt
rgent  surgery  in  patients  with  left-sided  IE.  This  should  be
pplied  to  right-sided  IE  and,  in  case  of  right  ventricular  fail-
re  with  increased  obstruction;  surgical  explantation  should
ot  be  delayed.  In  this  study,  two  patients  died  of  multiple
rgan  failure  due  to  severe  right  heart  failure,  secondary  to
evere  obstruction.
revention
revention  is  the  key  to  avoiding  Melody  valve  IE.  Implanta-
ion  should  be  done  once  a  total  dental  work-up  has  been
one  and  good  oral  hygiene  has  been  established.  Patients
nd  general  practitioners  should  be  informed  of  the  risk
f  IE,  to  avoid  prescription  of  antibiotics  without  further
ardiac  assessment  and  biological  tests  to  prompt  early
iagnosis.  The  association  of  IE  with  unprotected  invasive
rocedures  raises  the  question  of  the  need  for  modiﬁed
ntibioprophylaxis  guidelines  for  these  patients.  Antibi-
tic  prophylaxis  guidelines  should  perhaps  be  reviewed  and
dapted  for  each  patient.  Indeed,  according  to  the  new
uidelines,  only  dental  procedures  with  rupture  of  the
ucosa  require  oral  prophylaxis,  but  no  studies  have  been
onducted  so  far  to  monitor  the  effect  of  these  modiﬁed
uidelines  in  the  population  of  patients  with  serious  CHD
12,31].  Based  on  our  data  and  the  literature,  we  believe
hat  lifelong  AAT  should  be  recommended.  If  invasive  pro-
edures  are  planned,  discontinuation  of  antiplatelet  therapy
hould  be  discussed  with  the  cardiologist.
uture directions and limitations to the study
e  limited  the  study  to  a single  centre  intentionally,  to
llow  analysis  of  a  more  robust  dataset.  Practice  in  a  sin-
le  centre  is  unchanged  in  a  short  period  of  time,  providing
onsistent  data  for  analysis.  However,  because  of  the  low
ncidence  of  IE  in  a small  population  of  patients,  the  number
f  events  is  inevitably  limited.  Therefore,  complex  statis-
ics  and  powered  analyses  could  not  be  performed,  which
ight  explain  why  some  possible  risk  markers  (such  as  male
ex,  history  of  severe  infection,  history  of  endocarditis,  etc.)
ould  not  reach  statistical  signiﬁcance.  Multicentre  studies
re  needed  to  evaluate  larger  cohorts  with  larger  numbers
f  patients  with  IE,  to  delineate  risks  factors  more  accu-
ately  and  to  study  the  exact  role  of  aspirin  discontinuation
nd  unprotected  invasive  procedures  in  the  occurrence  of
E.  The  effects  of  turbulence  ﬂow  on  the  valve  structure
hould  be  examined.  This  study  suggests  that  a  multicen-
re  randomized  placebo-controlled  study  should  be  initiated
o  determine  if  AAT  should  be  continued  lifelong  or  for
 months  only.  Finally,  the  follow-up  of  patients  who  under-
ent  SAPIEN  PPVR  is  of  interest  to  determine  the  role  of  the
elody  valve  itself  in  the  development  of  IE.
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Conclusions
Early-  and  late-onset  de  novo  IE  of  the  prosthetic  Melody
valve  is  emerging  as  a  complication  of  PPVR.  In  our  series,
aspirin  discontinuation  and  invasive  medical  procedures
post-PPVR  turned  out  to  be  signiﬁcant  predictors  of  Melody
valve  IE.  Multicentre  studies  are  required  to  determine
risk  factors  in  larger  populations  with  larger  numbers  and
more  powerful  statistics.  In  light  of  these  results,  we  now
recommend  preimplantation  dental  work-up  as  prevention,
lifelong  full-dose  aspirin,  adapted  antibioprophylaxis,  close
monitoring  and  extensive  patient  and  general  practitioner
education  about  the  potential  risks  of  IE  after  PPVR  and
the  need  for  rapid  cardiological  assessment  in  case  of  unex-
plained  fever.
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